The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Slides:



Advertisements
Similar presentations
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Advertisements

Overview of Targeted Therapy Mechanisms November 11, 2011 Targeted Therapies and Biological Therapies SIG.
Schema for a human microbiome study
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.
Advances in Specific Immunotherapy for Prostate Cancer
Figure 7 Clinical options for HCC therapy
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Engineering regulatory T cells against factor VIII inhibitors
Nat. Rev. Clin. Oncol. doi: /nrclinonc
The PI3K/Akt signalling and its activation in cancer
Nat. Rev. Clin. Oncol. doi: /nrclinonc
The hallmarks of adenovirus infection
Schematic diagram of antibody drug conjugate
Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma  Darshil J. Shah, MD, MPH, Roxana S. Dronca,
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Antigen-induced regulatory T cells
Figure 1 A schematic representation of the HER2 signalling pathway
Figure 2 Co-stimulatory receptors as immunomodulatory targets
Figure 4 Combination immunotherapeutic approaches with imatinib
The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
(A) An overview of the JAK/STAT signalling pathway.
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Drug cycling with collateral sensitivity
Molecular approaches to HER2 targeted therapy
An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer Figure 1 from Eser et al. British Journal.
Model of the function of TBX2 in RMS.
Figure 2 from Sancho et al.
The cancer stem cell concept in cancer progression and metastasis
The putative genomic evolution of prostate cancer from normal epithelium to castrate-resistant, metastatic cancer Figure 2 from Mitchell and Neal British.
Figure 1 from B Zhu British Journal of Cancer (2015) 112, ; doi: /bjc
Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,
Microglia and the Immune Pathology of Alzheimer Disease
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
A hypothetical scheme targeting autophagy for glioblastoma sensitisation during radio-chemotherapy with TMZ Figure 1 from Michael I Achilleas G and.
Figure 1 The role of CTLA4 and PD1 in T cell activation
Targets for immunotherapy of liver cancer
Figure 2 Approaches to improve CAR-T-cell therapy
Figure 2 Site of action of checkpoint inhibitors and agonists being
Robert J Korst, MD, Ronald G Crystal, MD 
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Pattern Recognition Receptors
Figure 1 from M Holderfield
Molecular features of the colon during homeostasis and carcinogenesis
Figure 1 from T Schenk et al.
Mechanism of CTLA-4-induced immunosuppression.
Nat. Rev. Endocrinol. doi: /nrendo
Fbxw7 ablation in LICs for CML sensitises the cells to imatinib by preventing quiescence. Figure 2 from S Takeishi British Journal of Cancer (2014) 111,
HDACs class I, II, IV mutations in human cancer
In melanoma tumours expressing the BRAFV600E oncogene RAF inhibitor treatment decreases ERK activation resulting in tumour regression and increased survival.
Figure 1 Mechanisms of action of immunotherapy modalities
Mitochondrial priming model
Spectrum of cellular processes regulated by AXL activity
Figure 1 from D’Incalci et al.
Involvement of actin cytoskeletal reorganisation in EMT
The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc
Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.
Target antigens for ADCs in solid tumours
Macrophage differentiation and their role in tumourigenesis
Model of EphA/ephrin-A expression in GBM.
Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;
Releasing the Brakes on Cancer Immunotherapy
(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.
Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)
Presentation transcript:

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting cells (APC), T cells, and tumour cells Figure 1 from Cogdill et al. British Journal of Cancer Advance Online Publication 18 May 2017 doi:10.1038/bjc.2017.136 Several approaches exist to target Eph receptors. Kinase inactivating strategies include kinase inhibitors or blocking peptides or antibodies. Kinase activating strategies include ligand stimulation, activating antibodies or ligand peptide mimetics Strategies to deliver toxic payloads following receptor activation and internalisation include coupling of cytotoxic agents or radionuclides to Eph monoclonal antibodies. © 2017 The Author(s).